Xu Che

Xu Che

Auto-generated profile, based on publicly available information

Xu Che

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Pancreas
Verified
Journal Article
Closed access
WZWei Zhang
Wei Zhang
JZJianwei Zhang
Jianwei Zhang
XCXu Che
Xu Che
Objectives: The aim of this study was to compare the short-term and long-term outcomes of minimally invasive surgery (MIS) with those of open pancreas surgery (OPS) for the treatment of pancreatic neuroendocrine neoplasms (pNENs). Methods: Studies reporting the effects of MIS and OPS for pNENs, published on PubMed, Embase, and Cochrane Library before May 2020 were reviewed. Results: Seventeen cohort studies with a total of 1853 patients were eligible for analysis, including 655 patients in the MIS group and 1198 patients in the OPS group. The estimated blood loss, postoperative hospitalization time, overall complications, severe complications, spleen preservation, mortality, and recurrence in the MIS group were lower than those in the OPS group. The R0 rate, 3-year overall survival (OS), and 5-year OS in the MIS group were higher than those in the OPS group. There were no significant differences in operative time, postoperative pancreatic fistula, clinical postoperative pancreatic fistula, postoperative bleeding, reoperation, readmission, and 1-year OS. Conclusions: Minimally invasive surgery can reach lower recurrence rate, higher long-term survival rate, and better outcomes in terms of estimated blood loss, postoperative hospitalization time, R0 rate, mortality, overall complications, and severe complications for pNENs. More high quality studies need to be conducted for further verification.

26 August 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
WZWei Zhang
Wei Zhang
ZHZhangkan Huang
Zhangkan Huang
WWWen-Er Wang
Wen-Er Wang
XCXu Che
Xu Che
Objective: This article aims to evaluate the survival benefits of simple cholecystectomy, extended cholecystectomy, as well as scope regional lymphadenectomy for T2 gallbladder cancer (GBC) patients.Methods: We identified eligible patients from the Surveillance, Epidemiology, and End Results database. The confounding factors were controlled via propensity score matching. The log-rank test was utilized to compare overall survival. The multivariate Cox regression was then used to determine risk factors.Results: Overall, data from 1,009 patients were obtained. The median overall survival (OS) of 915 patients that underwent simple cholecystectomy was 15 months; the median OS of 94 patients that underwent extended cholecystectomy was 17 months. There were no significant differences before and after propensity score matching (p = 0.542 and p = 0.258). The patients who received regional lymphadenectomy did show significant survival benefit, compared to those who did not receive regional lymphadenectomy. Furthermore, this benefit is observed in the N0 stage, but not observed in the N1 stage. In addition, the OS of patients who received lymphadenectomy for four or more regions was significantly better than those who received one to three regions lymphadenectomy. Age, the scope of regional lymphadenectomy, N stage, and tumor size were identified as prognostic factors.Conclusions: Extended cholecystectomy was not observed to significantly improve postoperative prognosis of patients with T2 GBC. However, there was a significant survival benefit shown for those with regional lymphadenectomy, particularly for patients with negative lymph nodes. Future studies on the control of potential confounding factors and longer follow-ups are still needed.

29 September 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
XLXu Lin
Xu Lin
PWPeng Wang
Peng Wang
WZWei Zhang
Wei Zhang
WLWeiran Li
Weiran Li
TLTao Liu
Tao Liu
XCXu Che
Xu Che
Background: Cholangiocarcinoma (CCA), including intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) CCA, is a highly aggressive malignancy originating from bile duct. The prognosis of CCA is very poor, and the biomarker study is unsatisfactory compared with other common cancers.Materials and methods: In our study, we investigated the expression of dual-specificity phosphatase 11(DUSP11) in eight pairs of iCCAs, pCCAs, and dCCAs, and their corresponding tumor-adjacent tissues, as well as their tumor-adjacent tissues with qPCR. Moreover, we investigated the expression of DUSP11 in 174 cases of CCAs with immunohistochemistry, including 74 iCCAs, 64 pCCAs, and 36 dCCAs. We classified these patients into subsets with low and high expressions of DUSP11, and evaluated the correlations between the DUSP11 subsets and clinicopathological factors. With univariate and multivariate analyses, we assessed the correlation between DUSP11 and the overall survival (OS) rates in these CCA patients.Results: In all the CCA subtypes, DUSP11 was elevated in CCAs compared with their paired adjacent tissues. In iCCA, pCCA, and dCCA, the percentages of DUSP11 high expression were 44.59%, 53.85%, and 55.56%, respectively. In iCCA, high DUSP11 expression was significantly associated with an advanced T stage and a poor prognosis. However, the prognostic value of DUSP11 in pCCA and dCCA was not significant. To decrease the statistical error caused by the small sample size of the dCCA cohort, we merged pCCA and dCCA into extracellular CCA (eCCA). In the 101 cases of eCCA, DUSP11 expression was also not significantly associated with the prognosis.Conclusions: DUSP11 expression was associated with tumor infiltration and the OS rate in iCCA, but not in pCCA and dCCA. DUSP11 was an independent biomarker of iCCA indicating a poor prognosis. Our results suggested that a high expression of DUSP11 was a post-operational risk factor, and detecting DUSP11 could guide the individual treatment for patients with CCA.

1 June 2017 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
YZYing Zeng
Ying Zeng
ARAgnieszka A. Rucki
Agnieszka A. Rucki
XCXu Che
Xu Che
Lei ZhengLei Zheng
Lei Zheng
Pancreatic adenocarcinoma is still widely considered as a deadly disease even though there are substantial therapeutic developments in the past decade. Using combinational chemotherapy regimens, represented by gemcitabine plus nab-paclitaxel and FOLFIRINOX, was able to improve overall survival in patients with advanced disease to a limited extent. It has been a challenge to develop targeted therapies that are focused on the neoplasm cells of pancreatic adenocarcinoma. Recently, targeting the stroma and immune compartments of pancreatic adenocarcinoma has shown promising results. The paradigm of biologics drug development therefore has been shifted by extending to these exciting areas. Although some of the preclinical and clinical researches in targeting the tumor microenvironment of pancreatic adenocarcinoma have shown promising results, others have resulted in controversial findings. Both comprehensive and in-depth researches on the basic science of the tumor microenvironment of pancreatic adenocarcinoma are thus warranted for the development of effective biologics that target the tumor microenvironment. Moreover, an ideal treatment for pancreatic adenocarcinoma shall be a combination of targeting both neoplastic cells and the tumor microenvironment.

9 April 2025 in Romanian Journal of Oral Rehabilitation
Verified
Journal Article
Open access
WHWendan He
Wendan He
BDBoyue Deng
Boyue Deng
ZWZhongdong Wang
Zhongdong Wang
XCXiaoxia Che
Xiaoxia Che
Peri-miniscrew implant inflammation (PMSII) is a common complication after orthodontic anchorage, causing chronic progressive inflammation. This study aimed to investigate the role of miR-125a-5p in the regulation of macrophage polarization. THP-1 cells were induced to differentiate into macrophages. We modulated miR-125a-5p levels in THP-1 cells through mimics and inhibitors and cocultured these with HGF-1 cells to simulate the physiological environment. Our results indicated that increased miR-125a-5p levels in THP-1 cells induced M2-like macrophage polarization, enhanced cell proliferation and stimulated cell migration, whereas these effects were counteracted by miR-125a-5p knockdown. Bioinformatics analysis predicted target genes of miR-125a-5p that were enriched in the HIF-1 pathway, and differential expression of miR-125a-5p regulated the activity of related proteins in this pathway. Crosstalk effect of miR-125a-5p-induced macrophage polarization on HGF-1 cells revealed that more cells lost their spindle shape and were closer to a round shape in miR-125a-5p high-expressing THP-1 cocultures with HGF-1. Further studies suggested that miR-125a-5p was involved in the growth and proliferation of gingival fibroblasts through macrophages. Collectively, our findings suggest that miR-125a-5p is a potential target for regulating macrophage polarization, which provides new insights for the clinical treatment of peri-implantitis.